Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics
View/ Open
Author
Yuan, Gengyang
Jankins, Tanner C.
Patrick, Christopher G.
Philbrook, Phaethon
Sears, Olivia
Hatfield, Stephen
Sitkovsky, Michail
Ondrechen, Mary Jo
Pollastri, Michael P.
Jones, Graham B.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1155/2017/4852537Metadata
Show full item recordCitation
Yuan, G., T. C. Jankins, C. G. Patrick, P. Philbrook, O. Sears, S. Hatfield, M. Sitkovsky, et al. 2017. “Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics.” International Journal of Medicinal Chemistry 2017 (1): 4852537. doi:10.1155/2017/4852537. http://dx.doi.org/10.1155/2017/4852537.Abstract
Antagonism of the adenosine A2A receptor on T cells blocks the hypoxia-adenosinergic pathway to promote tumor rejection. Using an in vivo immunoassay based on the Concanavalin A mouse model, a series of A2A antagonists were studied and identified preladenant as a potent lead compound for development. Molecular modeling was employed to assist drug design and subsequent synthesis of analogs and those of tozadenant, including fluorinated polyethylene glycol PEGylated derivatives. The efficacy of the analogs was evaluated using two in vitro functional bioassays, and compound 29, a fluorinated triethylene glycol derivative of preladenant, was confirmed as a potential immunotherapeutic agent.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671725/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651930
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)